Evidence map›Paper›PMID 24824043›Full record

ArticleAIDS and behavior2014

Syringe exchange in the United States: a national level economic evaluation of hypothetical increases in investment.

Trang Quynh Nguyen, Brian W Weir, Don C Des Jarlais, Steven D Pinkerton, David R Holtgrave

Abstract read
In one paragraph

Article in AIDS and behavior, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Return on investment of public health interventions: a systematic review.Journal of epidemiology and community health · 2017
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Trang Quynh NguyenDepartment of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, nqtrang.hanoi@gmail.com.
Brian W Weir
Don C Des Jarlais
Steven D Pinkerton
David R Holtgrave
Johns Hopkins University · USMedical College of Wisconsin · USMount Sinai Beth Israel · US

Funding

Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Event-level correlates of substance use, violence, and HIV risk behaviorF31DA026763 · NIDA · JOHNS HOPKINS UNIVERSITY · PI WEIR, BRIAN WILSON · 2009 to 2011
$124k
NIAID NIH HHS T32 AI102623NIDA NIH HHS F31 DA026763
6 · The paper itself

Abstract

To examine whether increasing investment in needle/syringe exchange programs (NSPs) in the US would be cost-effective for HIV prevention, we modeled HIV incidence in hypothetical cases with higher NSP syringe supply than current levels, and estimated number of infections averted, cost per infection averted, treatment costs saved, and financial return on investment. We modified Pinkerton's model, which was an adaptation of Kaplan's simplified needle circulation theory model, to compare different syringe supply levels, account for syringes from non-NSP sources, and reflect reduction in syringe sharing and contamination. With an annual $10 to $50 million funding increase, 194-816 HIV infections would be averted (cost per infection averted $51,601-$61,302). Contrasted with HIV treatment cost savings alone, the rate of financial return on investment would be 7.58-6.38. Main and sensitivity analyses strongly suggest that it would be cost-saving for the US to invest in syringe exchange expansion.

Indexed as

Cost-Benefit AnalysisCost SavingsFemaleHealth Care CostsHIV InfectionsHumansMaleModels, EconomicNeedle-Exchange ProgramsSubstance Abuse, IntravenousUnited States

Identifiers

PMID24824043
PMCPMC4211599
OpenAlexW2014202174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.